Cervical Cancer in African Americans: Risk, Screening, and Outcomes

Key Facts at a Glance

What Cervical Cancer Is and How It Develops

Cervical cancer is a preventable malignancy of the cervix driven primarily by persistent infection with high-risk human papillomavirus (HPV). Most sexually active individuals encounter HPV at some point, but in a minority, oncogenic types (especially HPV 16 and 18) evade clearance, leading to progressive cervical cell changes. Routine screening with cytology (Pap test) and/or HPV testing can identify precancerous lesions before they become invasive. When found early, treatment outcomes are excellent; late-stage disease is more difficult to manage and carries higher mortality.

Why Cervical Cancer Disparities Matter for African American Women

African American women in the United States experience higher cervical cancer incidence and mortality than White women, even after adjustment for age. These disparities reflect a combination of structural factors—such as unequal access to high-quality care, lower health insurance coverage, medical mistrust rooted in historical injustices, and neighborhood-level social determinants—as well as individual-level barriers like competing work and childcare demands, transportation issues, and clinician factors that influence screening uptake and follow-up. Understanding these upstream drivers is essential for designing effective, culturally grounded interventions that reduce inequities over time.

How HPV Vaccination Reduces Risk Over Time

Vaccination as a Cancer Prevention Tool

The HPV vaccine is highly effective at preventing infection from the vaccine-targeted HPV types when administered before exposure. Routine vaccination is recommended at ages 11–12, with catch-up vaccination through age 26 and shared clinical decision-making up to age 45 in certain cases. Real-world data show substantial declines in vaccine-type HPV prevalence among vaccinated cohorts, alongside declines in cervical precancers. Expanding HPV vaccination coverage in African American communities is a long-term strategy to narrow cervical cancer disparities, alongside efforts to improve linkage from screening to treatment.

Understanding Cervical Cancer Screening Options and Timing

Primary HPV Testing

Primary HPV testing detects oncogenic HPV DNA and is preferred by many guidelines due to its strong negative predictive value. In settings with high-quality HPV testing, intervals can be extended to every five years, which can ease the burden on patients and systems while maintaining effectiveness.

CofTesting (Pap Test Plus HPV Test)

CofTesting combines a Pap test with an HPV test. When both results are negative, the short-term risk of cervical cancer is very low, allowing for longer screening intervals in many guidelines. This approach may be particularly useful in populations with variable access to follow-up care, where a single combined evaluation can provide reassurance and inform next steps.

Visual Inspection with Acetic Acid (VIA)

VIA is a low-resource, low-cost method suitable for limited-resource or outreach settings. After applying acetic acid to the cervix, areas that turn white are examined; if abnormalities are seen, the patient is referred for colposcopy and treatment. While less precise than cytology or HPV testing, VIA can expand screening access in community-based programs.

What Happens When Screening Finds Something Abnormal

An abnormal screening test does not mean cancer. Most abnormalities represent transient HPV infections or low-grade changes that regress on their own. Higher-grade lesions are typically referred for colposcopy, where a clinician uses magnification and acetic acid to map the transformation zone and obtain targeted biopsies. Treatment for precancer may include excisional procedures (e.g., LEEP, cold knife conization) or ablation, depending on lesion size, location, and reproductive plans. Close follow-up ensures persistence is addressed while minimizing overtreatment of self-resolving changes.

Diagnosis, Staging, and Treatment Pathways

If invasive cancer is confirmed, staging determines the appropriate treatment. Early-stage disease may be managed with fertility-sparing surgery or definitive radiation, while more advanced cases often require multimodality care involving surgery, chemotherapy, and/or radiation. Prognosis is strongly stage-dependent: localized tumors have high cure rates, whereas metastatic disease presents greater challenges. Treatment planning should incorporate patient preferences, comorbidities, and access to specialized care, with attention to minimizing delays from referral to treatment.

Practical Steps to Reduce Your Risk and Improve Outcomes

• Start screening on time: follow age- and risk-based guidance for your care environment.
• Complete the HPV vaccine series if eligible; discuss catch-up vaccination with your clinician.
• Keep a record of screening and vaccination dates and ensure timely follow-up after any abnormal result.
• Ask your clinician about access options—extended hours, community clinics, or telehealth—to reduce barriers.
• Bring an advocate to appointments if worries about mistrust or communication affect your care experience.
• Engage community organizations that partner with trusted providers to navigate screening and treatment pathways.

Community and Systemic Strategies That Work

Reducing cervical cancer disparities in African American communities requires coordinated efforts across sectors. Community health workers and patient navigators can link individuals to screening and treatment; faith-based organizations and local clinics can host education and outreach. Health systems can implement reminder-recall systems, streamline access to colposcopy, and embed HPV vaccination into routine adolescent care. Qualitative research in affected communities helps tailor messaging and address historical concerns, fostering trust and sustained engagement over time.